Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial - Tabernero, Josep; Satoh, Taroh; Dasari, Arvind; Lonardi, Sara; Eng, Cathy; Garcia-Carbonero, Rocio; Elez, Elena; Yoshino, Takayuki; Sobrero, Alberto F.; Yao, James C.; Kasper, Stefan; Arnold, Dirk; et al. (Journal of clinical oncology, 2024)